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ABSTRACT The aim of this paper is to describe our surgical 
procedure for the treatment of osteonecrosis of the femo-
ral head using a minimally invasive technique. We have 
limited the use of this procedure for patients with pre-col-
lapse osteonecrosis of the femoral head (Ficat Stage I or II). 
To treat osteonecrosis of the femoral head at our institution 
we currently use a combination of outpatient, minimal-
ly invasive iliac crest bone marrow aspirations and blood 
draw combined with decompressions of the femoral head. 
Following the decompression of the femoral head, adult 
mesenchymal stem cells obtained from the iliac crest and 
platelet rich plasma are injected into the area of osteone-
crosis. Patients are then discharged from the hospital using 
crutches to assist with ambulation. This novel technique 
was utilized on 77 hips. Sixteen hips (21%) progressed to 
further stages of osteonecrosis, ultimately requiring total 
hip replacement. Significant pain relief was reported in 
86% of patients (n = 60), while the rest of patients reported 
little or no pain relief. There were no significant complica-
tions in any patient. We found that the use of a minimally 
invasive decompression augmented with concentrated 
bone marrow and platelet rich plasma resulted in signifi-
cant pain relief and halted the progression of disease in a 
majority of patients.
Osteonecrosis of the femoral head (ONFH) occurs when 
the cells of the trabecular bone and marrow in the femoral 
head spontaneously die, leading to fracture and collapse 
of the articular surface (1,2). In the US, every year ONFH oc-
curs in 10 000-20 000 adults between the ages of 20 and 60 
(1,3,4). Once collapse occurs, severe pain ensues, and the 
disease course rarely regresses (5-8). In order to halt dis-
ease progression and provide pain relief, 80% of patients 
suffering from ONFH will require a total hip arthroplasty 
(THA); typically at a younger age than patients undergoing 
a THA for osteoarthritis (9-11).
Although ONFH is a common indication for THA, the eti-
ology of the disease is still unknown (12,13). ONFH is 
thought to be a multifactorial disease, with patients re-
porting a history of exposure to one or more risk factors, 
including trauma to the hip, alcohol abuse, corticosteroid 
use, hemoglobinopathies, pregnancy, coagulopathies, or-
gan transplant, chemotherapy, Caisson disease, HIV, and 
autoimmune conditions; however in some patients the 
risk factor remains unknown, and the disease is termed “id-
iopathic” ONFH (12-16). Recent studies looking at the gen-
tics risks of ONFH have resulted in identifying an autosom-
al dominant mutation in collagen type II gene (COL2 A1 
gene) (17); which has been associated with genetic poly-
morphisms in alcohol metabolizing enzymes and the drug 
transport proteins (18,19).
If the disease course is recognized before collapse of the 
subchondral bone and cartilage, patients can be treated 
with core decompression of the femoral head including Fi-
cat Stage I or II (12,20,21). This technique has been used 
for over four decades, however randomized control trials 
have failed to show that this procedure alone halts dis-
ease progression and collapse (4). Recently, concentrated 
bone marrow autograft has been used to augment the 
decompression site to attempt to repopulate the femo-
ral head with human mesenchymal stem cells (hMSC) 
(13,22,23). This aim of this paper is to describe our 
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surgical technique and early clinical results using autolo-
gous bone marrow concentrate with platelet rich plasma 
and a minimally invasive decompression for the treatment 
of ONFH.
SuRgical TecHnique
The patient is placed supine on a radiolucent table and 
general anesthesia is performed. Fluoroscopic imaging is 
used at this time to ensure that adequate anterior-poste-
rior (AP) and frog-leg lateral images can be obtained with 
the patient’s position. The operative hip/hips and both iliac 
crests are prepped and draped into the surgical field in a 
sterile manner (Figure 1). Two grams of cefazolin should be 
given at this time. The procedure begins by obtaining iliac 
bone marrow aspirate. A 2-3-mm incision is made over that 
anterior aspect of each anterior iliac crest. When the iliac 
crest is visible, the trochar (Marrowstim, Biomet Biologics, 
Warsaw, IN, USA) can be inserted into the iliac crest in be-
tween the two tables of ilium and bone marrow can be as-
pirated into 10 mL-syringes. We use the Bio-Cue System (Bi-
omet Biologics) to concentrate the bone marrow aspirate 
obtained. Each vial requires 57 mL of bone marrow aspi-
rate mixed with 3 mL of heparin to prevent clot formation. 
A single vial produces 6 mL of concentrated bone marrow 
aspirate, and we typically utilize two vials per hip. Once col-
lected, the vials are placed in a centrifuge for 15 minutes to 
adequately concentrate the mononuclear fraction of blood 
that contains the mesenchymal progenitor cells. Addition-
ally, 120 mL of anticoagulated blood are placed into two 
additional separate vials and centrifuged for 15 minutes. 
Approximately 12 mL of platelet rich plasma is obtained.
Hip decoMpReSSion
While the bone marrow and blood are being centrifuged, 
we shift our attention to the hip decompression. A 1-cm 
incision is made over the lateral aspect of the femur just 
below the vastus ridge of the trochanter. The position 
should be confirmed by fluoroscopy. Typically power in-
struments are not necessary except if entry into the lateral 
cortex is difficult. The starting point is maintained proximal 
FiguRe 1. patient with iliac crest aspirators in place, with 
bilateral hips prepared for decompression and injection of 
concentrated bone marrow (published with permission from 
Sierra RJ). alternative procedure for osteonecrosis of the femo-
ral head, Figure 2 (24).
FiguRe 2. anteroposterior (A) and frog-leg lateral (B) radio-
graph showing the decompression trochar in the area of 
necrosis (published with permission from Sierra RJ). alterna-
tive procedure for osteonecrosis of the femoral head, Figures 
3a and 3B (24).
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to the level of the lesser trochanter and distal to the vas-
tus ridge. When the ideal starting point has been obtained 
the trochar is advanced from lateral to medial under bipla-
nar fluoroscopy; taking care to verify the position of the 
trochar as the tip needs to end “in” the necrotic lesion. A 
6-mm trochar is utilized for the decompression. The tro-
char is advanced into the necrotic lesions with gentle mal-
let taps. Typically, a change in pitch is noted when the tro-
char has reached the area of necrosis (Figure 2). The areas 
of necrosis can be entered with the trochar but should not 
be advanced within 5 mm of subchondral bone to avoid 
collapse. Correct trochar positioning is confirmed under 
biplanar fluoroscopy. The inner core of the trochar is re-
moved, leaving the 6 mm trochar in the necrotic portion 
of the femoral head.
inJecTion oF concenTRaTed Bone MaRRow
At this time, the contents of the bone marrow concentrate 
and the platelet-rich plasma have completed the centrif-
ugation process. Approximately 12 mL of each should 
be obtained. They are combined in a 30 mL-syringe in a 
sterile manner. This can be doubled if both hips are to be 
injected. The contents of the 30 mL-syringe are then in-
jected into the trochar, which should be positioned in the 
necrotic lesion of the femoral head. Due to the sclerotic 
nature of the lesions, it may require significant pressure 
to inject the contents from the syringe (Figure 3). If exces-
sive resistance is met, the trochar can be retracted while 
confirming that the tip remains in the area of necrosis. This 
will increase the space available to inject while ensuring 
that the mesenchymal stems cells are delivered to the cor-
rect area. After injecting the contents of the syringe, the 
bone marrow/PRP solution will likely flow retrograde due 
to pressure gradients. To prevent this retrograde backflow, 
the trochar can be removed, and reinserted into the previ-
ous track at a different angle in order to push cancellous 
bone into the tract.
poST-opeRaTive caRe
All patients were discharged home the day of surgery. 
Patients are allowed to weight bear as tolerated with the 
use of crutches for approximately 2 weeks. In patients that 
undergo bilateral procedures, we recommend the use of 
crutches until hip pain subsides, allowing for full pain-free 
ambulation. Some patients have an increase in pain initial-
ly after the injection. This pain is unlikely to last more than 
3 months and the majority of patients have significant pain 
relief within a few weeks. Because the technique described 
utilizes a smaller trochar than is typically used for core de-
compression, it allows patients to weight bear as tolerated 
immediately postoperatively. Patients are discharged on 
10 mg of Simvastatin daily until healing or collapse of the 
lesion occurs. We found that many patients only use the 
crutch for the first week.
ouR ReSulTS
At our institution, hip decompression with the intro-
duction of concentrated bone marrow and platelet rich 
plasma was performed on 73 hips. We retrospectively 
reviewed this patient population under institutional re-
view board (IRB) approval from our institution. Patients 
consented to current research study under the protocol 
set forth by the IRB committee. Patients were followed 
for an average of 17 months. Twenty-five patients under-
went unilateral decompression and 24 underwent bilat-
eral decompression. Preoperative x-rays and MRI was ob-
tained on all patients. Thirty-six left hips and 37 right hips 
underwent decompression. The average age of patients 
was 43 years. Fifty-seven patients had Stage I and 16 pa-
tients had stage II. Four hips were re-injected due to con-
tinued symptoms without radiographic evidence of pro-
gression. Sixteen hips (21%) progressed to further stages 
of osteonecrosis, ultimately requiring total hip replace-
ment (Figure 4). There were no significant complications 
in any patient undergoing this procedure. Two patients 
were noted to have post-operative trochanteric bursi-
tis at immediate follow-up, however this was managed 
non-operatively. The top three underlying etiologies 
included steroids (n = 44), alcohol (n = 10), and id-
FiguRe 3. injection of bone marrow concentrate into the area 
of necrosis (published with permission from Sierra RJ). alterna-
tive procedure for osteonecrosis of the femoral head, Figure 
4 (24).
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iopathic ONFH (n = 9). Significant pain relief was reported 
in 86% of patients (n = 60), while the rest of patients re-
ported little or no pain relief.
oRiginal deScRipTion
The introduction of mesenchymal stem cells into the fem-
oral head for avascular necrosis was originally described in 
2002 (22). At this time, physicians were disappointed with 
the results of a standard core decompression and believed 
that the introduction of bone marrow concentrate could 
introduce mesenchymal stem cells into an area of necro-
sis. A retrospective review of 116 patients and 189 hips de-
scribed a technique that utilized a trephine approach to 
enter the area of necrosis under fluoroscopy and then in-
ject concentrated bone marrow directly into this area. It 
found excellent results in patients who were pre-collapse 
(stage I or II). In this group, 9 out of 145 hips required a total 
hip arthroplasty at minimum five-year follow-up (22). How-
ever, in patients who had already collapsed (stage III or IV), 
25 out of 44 hips required a THA. The study also evaluated 
the underlying etiology that predisposed the patient to 
AVN by correlating the etiology of necrosis to the need for 
subsequent THA and the number of mesenchymal stem 
cell colony forming units (22). The three most common 
factors were sickle cell disease, alcohol use, and corticos-
teroid use (22).
RandoMized TRialS
The original work by Hernigou was a retrospective study 
that popularized the addition of bone marrow concentrate 
to a core decompression (22). The information obtained 
from the study have been proven very beneficial in identi-
fying the procedure and etiologic data, however the study 
did not compare the results with core decompression in 
a prospective manner. Since this study, at least 4 studies 
have prospectively compared the results of standard core 
decompression and core decompression with autologous 
bone marrow introduction.
FiguRe 4. a 43-year-old female on steroids for cancer treatment presents with bilateral hip involvement. upper left: anteroposterior 
(ap) pelvis radiograph taken on presentation. lower left: ap of the left femur taken on presentation. upper right: T2 coronal oblique 
MRi showing significant bilateral head involvement prior to treatment. lower right: ap pelvis shows complete collapse of the left 
femoral head resulting in total hip arthroplasty 1 year post-operative.
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In 2004, Gangji et al in a prospective randomized controlled 
trial compared the results of core decompression with core 
decompression with bone marrow (CDBM) (23). The study 
specifically looked at patients with stage I-II AVN, and ex-
cluded all patients with post-collapse AVN. Eight hips un-
derwent core decompression and 10 hips underwent 
CDBM. The patients’ age and underlying cause of AVN were 
similar. During the 24-month period, the CDBM group had 
a statistically significant decrease in pain (P = 0.021). The 
Lequesne and WOMAC indices were also significantly im-
proved. At follow-up, 5 of 8 hips in the core decompression 
group collapsed compared to only 1 of 10 in the CDBM 
group. The author also found that the volume of involve-
ment of AVN of the femoral head in the CDBM group had 
significantly decreased from 15.6% pre-op to 10.1% at 24 
months. In the core decompression group, it significantly 
increased from 16.7% pre-op to 20.6% (P = 0.036). Finally, 
both methods were found to have no major complications 
(23). This paper was followed-up in 2011 with 5-year of clin-
ical follow-up (25). At the 5-year time point, 8 of 11 hips in 
the core decompression group progressed to fracture and 
collapse, while in the CDBM group only 3 of 13 progressed 
to collapse (25).
Chang et al conducted a prospective trial, which includ-
ed 14 hips that underwent core decompression or CDBM 
(26). The randomization included involvement of the left 
or right hip. CDBM group had a significantly lower Harris 
Hip score and area of femoral head necrosis (P < 0.05). One 
patient in the core decompression group collapsed com-
pared to no patients in the CDBM group. No significant 
complications were noted in either group. Due to the small 
number of patients in each group, it is difficult to draw any 
definitive conclusions from this study.
In a recent prospective trial by Sen et al, 25 hips under-
went core decompression and 26 hips underwent CDBM 
(27). All patients were followed for a minimum of two years. 
At the final follow-up, the CDBM group had significantly 
higher Harris Hip Scores. They found no difference in ra-
diographic or MRI improvement between the groups. The 
authors also noted that pre-operative etiologies also signif-
icantly affected outcome and that patients with poor pre-
op Harris Hip score, x-ray changes, edema, and effusion on 
MRI had better results in the CDBM group.
Zhao et al also looked at a similar group of patients (13). 
Fifty-one hips underwent core decompression and 53 hips 
underwent CDBM. Ten patients in the core decompression 
group progressed and eventually required THA or vascu-
larized fibula graft. Only two hips in the CDBM group re-
quired vascularized fibula graft. Patients who underwent 
CDBM also had a significantly higher Harris Hip score at the 
final follow-up. All groups excluding patients with pre-op-
erative IIa lesions in the core decompression group had a 
significant decrease in volumetric involvement of the fem-
oral head. No significant complications were found in ei-
ther group. They also concluded that the size and the loca-
tion of the AVN lesion was likely the most important factor 
in patient outcomes.
In conclusion, the combination of hip decompression 
and injection of mesenchymal stem cells into the necrot-
ic lesion provides satisfactory results in patients with early 
stage ONFH and can lead to complete resolution of the 
necrotic lesion. The procedure is simple, with a low com-
plication rate and the patients are allowed to weight bear 
as tolerated allowing them an early return to function and 
activities of daily living.
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